Clinical trial
Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study
NCT00242801 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00242801 |
|---|---|
| Title | Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study |
| Official title | A Double Blind,Placebo Controlled,Parallel Group,Multicentre,Randomised,Phase Iii Survival Study Comparing ZD1839 (IRESSA™)(250mg Tablet) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients With Advanced NSCLC Who Have Received One Or Two Prior Chemotherapy Regimens And… |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | NSCLC |
| Intervention type | Drug |
| Interventions | Gefitinib |
| Enrollment | 1,692 |
| Start date | Jul 1, 2003 |
| Completion | Apr 1, 2005 |
| First posted | Oct 21, 2005 |
| Last update posted | Apr 23, 2009 |
| Countries | Argentina, Australia, Brazil, Bulgaria, Canada, Chile, Estonia, Germany, Greece, Hungary, India, Ireland and 20 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: